A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
2021
Denise Haslwanter | M. Eugenia Dieterle | Anna Z. Wec | Cecilia M. O’Brien | Mrunal Sakharkar | Catalina Florez | Karen Tong | C. Garrett Rappazzo | Gorka Lasso | Olivia Vergnolle | Ariel S. Wirchnianski | Robert H. Bortz | Ethan Laudermilch | J. Maximilian Fels | Amanda Mengotto | Ryan J. Malonis | George I. Georgiev | Jose A. Quiroz | Daniel Wrapp | Nianshuang Wang | Kathryn E. Dye | Jason Barnhill | John M. Dye | Jason S. McLellan | Johanna P. Daily | Jonathan R. Lai | Andrew S. Herbert | Laura M. Walker | Kartik Chandran | Rohit K. Jangra
The U.S. FDA has issued emergency use authorizations (EUAs) for multiple investigational monoclonal antibody (MAb) therapies for the treatment of mild to moderate COVID-19.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
